Patients with moderate to severe OSA taking phentermine and topiramate extended-release capsules achieved significant improvements in key measures of OSA and cardiovascular risk factors.
Read More
Company plans cost reduction plan for 2013 of more than $2 million
Read More
The tasimelteon Non-24-Hour Disorder program continues toward the goal of a projected mid-2013 New Drug Application filing with the FDA.
Read More
The aura6000 THN Sleep Therapy System named Best New Product by Neurotech Reports
Read More
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, has ended enrollment in the first global pilot study to treat central sleep apnea with an implantable system.
Read More